Maintenance Infliximab Treatment Is Associated with Improved Bone Mineral Density in Crohn's Disease

@article{Bernstein2005MaintenanceIT,
  title={Maintenance Infliximab Treatment Is Associated with Improved Bone Mineral Density in Crohn's Disease},
  author={Michael Bernstein and Sue P. Irwin and Gordon R. Greenberg},
  journal={The American Journal of Gastroenterology},
  year={2005},
  volume={100},
  pages={2031-2035}
}
OBJECTIVES:Diminished bone mineral density (BMD) is a recognized complication of Crohn's disease (CD). The mechanisms underlying bone loss are unclear but may include a direct effect of inflammatory cytokines related to disease activity. Because tumor necrosis factor alpha (TNF-α) plays a central role in the pathogenesis of CD inflammation, we evaluated the effect on BMD of maintenance treatment with infliximab in patients with CD.METHODS:BMD of the lumbar spine (L2-L4) and proximal left femur… 

Figures and Tables from this paper

Improvement of lumbar bone mass after infliximab therapy in Crohn's disease patients.
TLDR
Infliximab therapy improved lumbar bone mass independent of nutritional status, suggesting that TNFalpha plays a role in bone loss in Crohn's disease.
Effects of infliximab on markers of inflammation and bone turnover and associations with bone mineral density in patients with ankylosing spondylitis
TLDR
While many significant correlations were observed between BMD scores of the hip and spine and biomarker levels, high baseline osteocalcin levels and early increases in BAP were consistently associated with increases inBMD scores.
Inflammation Is The Main Determinant of Low Bone Mineral Density in Pediatric Inflammatory Bowel Disease
TLDR
In children with IBD, inflammation is an important determinant of bone loss, as shown by the correlation of BMAD with serum IL‐6 and with disease activity indexes as well as by the beneficial effect of IFX on bone density.
Infliximab Therapy Improves the Bone Metabolism in Fistulizing Crohn’s Disease
TLDR
The results suggest that TNF-α has an important role in the alteration of bone metabolism in fistulizing CD patients and the beneficial effect of infliximab to the bone metabolism is more expressive in patients whose Fistulizing disease improves with this therapy.
Improvement in biomarkers of bone formation during infliximab therapy in pediatric Crohn's disease: results of the REACH study.
  • M. Thayu, M. Leonard, R. Baldassano
  • Medicine
    Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
  • 2008
Changes of OPG and RANKL concentrations in Crohn's disease after infliximab therapy
TLDR
IFX therapy decreased the OPG concentration in CD patients significantly, and in parallel, the serum bone resorption marker (bCL) also decreased.
Changes of OPG and RANKL concentrations in Crohn's disease after infliximab therapy.
TLDR
IFX therapy decreased the OPG concentration in CD patients significantly and in parallel, the serum bone resorption marker (bCL) also decreased, and Concentrations of bone formation marker (OC) and sRANKL increased during the same period; however, those changes were not statistically significant.
Alendronate improves low bone mineral density induced by steroid therapy in Crohn's disease.
TLDR
The BMD of Japanese CD patients was decreased depending on the total amount of steroid administered, and oral alendronate improved the loss of BMD.
A 1-year prospective study of the effect of infliximab on bone metabolism in inflammatory bowel disease patients
TLDR
Osteoblast culture results suggest that IBD patients may have increased osteoblast viability, but reduced differentiation, which has implications for bone strength.
...
...

References

SHOWING 1-10 OF 40 REFERENCES
Bone mineral density in patients with recently diagnosed inflammatory bowel disease.
TLDR
Subsequent development of osteoporosis in patients with IBD seems to be a phenomenon related to the disease process and/or the treatment modalities of IBD, which was not significantly decreased compared with population controls.
Increase in bone mineral density of patients with spondyloarthropathy treated with anti-tumour necrosis factor α
TLDR
It is suggested that a benefit of anti-tumour necrosis factor α therapy on BMD in patients with SpA may be through an uncoupling effect on bone cells.
Bone mineral density in Crohn's disease: a longitudinal study of budesonide, prednisone, and nonsteroid therapy
TLDR
Patients with CD receiving maintenance treatment for 2 yr with prednisone show little change in BMD, whereas treatment with budesonide may be associated with LS and FN bone loss, whereas Budesonide does not confer an advantage over low-doseprednisone for the preservation of BMD.
Genetic factors determine extent of bone loss in inflammatory bowel disease.
TLDR
Genetic variations in the IL-6 and IL-1ra gene identify IBD patients at risk for increased bone loss.
Low-Dose Prednisone Induces Rapid Reversible Axial Bone Loss in Patients with Rheumatoid Arthritis
TLDR
The first randomized, placebo-controlled study of the initial effects of low-dose prednisone on bone mineral density in patients with active RA, and the results are reported, which suggest that these drugs may underestimate the effects of these drugs on bone.
Metabolic bone disease in patients with inflammatory bowel disease.
TLDR
It is shown that newly diagnosed epidemiologists and statisticians busy for years, but patients with Crohn’s disease had significantly reduced BMD, and early indications are that these effects and associations BMD as compared with newly diagnosed patients with are weak and overshadowed by the effect of the IBD ulcerative colitis.
Randomized trial of etidronate plus calcium and vitamin D for treatment of low bone mineral density in Crohn's disease.
  • J. Siffledeen, R. Fedorak, G. Greenberg
  • Medicine
    Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
  • 2005
Evaluation of bone mineral density in inflammatory bowel disease: current safety focus.
...
...